[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi:  10.3322/caac.21660
[2] MILLER K D, NOGUEIRA L, MARIOTTO A B, et al. Cancer treatment and survivorship statistics, 2019[J]. CA Cancer J Clin, 2019, 69(5):363-385. doi:  10.3322/caac.21565
[3] CHEN P X, LIU Y H, WEN Y K, et al. Non-small cell lung cancer in China[J]. Cancer Commun (Lond), 2022, 42(10):937-970. doi:  10.1002/cac2.12359
[4] CHEN W Q, ZHANG S W, ZOU X N, et al. Cancer incidence and mortality in China, 2006[J]. Chin J Cancer Res, 2011, 23(1):3-9. doi:  10.1007/s11670-011-0003-9
[5] HERBST R S, MORGENSZTERN D, BOSHOFF C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689):446-454. doi:  10.1038/nature25183
[6] THAI A A, SOLOMON B J, SEQUIST L V, et al. Lung cancer[J]. Lancet, 2021, 398(10299):535-554. doi:  10.1016/S0140-6736(21)00312-3
[7] KAUR J, ELMS J, MUNN A L, et al. Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy[J]. Crit Rev Oncol, 2021, 164(Suppl C):103417. doi:  10.1016/j.critrevonc.2021.103417
[8] MOK TSK, WU YL, KUDABA I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019, 393(10183):1819-1830. doi:  10.1016/S0140-6736(18)32409-7
[9] RECK M, REMON J, HELLMANN M D. First-line immunotherapy for non-small-cell lung cancer[J]. J Clin Oncol, 2022, 40(6):586-597. doi:  10.1200/JCO.21.01497
[10] WATANABE H, OKADA M, KAJI Y, et al. New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)[J]. Gan to Kagaku Ryoho, 2009, 36(13):2495-2501.
[11] GEORGIEVA M, DA SILVEIRA NOGUEIRA LIMA JP, AGUIAR P JR, et al. Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer[J]. Lung Cancer, 2018, 124:248-254. doi:  10.1016/j.lungcan.2018.08.018
[12] LIU Q, TAN C Q, YI L D, et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer[J]. PLoS One, 2021, 16(11):e0258605. doi:  10.1371/journal.pone.0258605
[13] XIE Q, ZHENG H, SU N, et al. Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China[J]. BMJ Open, 2022, 12(8):e061592. doi:  10.1136/bmjopen-2022-061592
[14] NAFEES B, STAFFORD M, GAVRIEL S, et al. Health state utilities for non small cell lung cancer[J]. Health Qual Life Outcomes, 2008, 6:84. doi:  10.1186/1477-7525-6-1
[15] ATTEMA A E, BROUWER W B F, CLAXTON K. Discounting in economic evaluations[J]. PharmacoEconomics, 2018, 36(7):745-758. doi:  10.1007/s40273-018-0672-z
[16] 刘国恩. 中国药物经济学评价指南2020[M]. 北京: 中国市场出版社, 2020: 27-47.
[17] 江苏省统计局. 2019年江苏省国民经济和社会发展统计公报[EB/OL]. (2020-03-03)[2020-12-10]. https://data.stats.gov.cn/search.htm?s=GDP.
[18] 安琪, 查镜凯, 徐伟. 帕博利珠单抗用于治疗非小细胞肺癌的药物经济学评价文献综述[J]. 中国药物经济学, 2023, 18(2):5-10.